Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Fiche publication


Date publication

juin 2021

Journal

BMC immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Dr MARTIN Etienne, Dr MIRJOLET Céline, Dr VULQUIN Noémie, Dr BOUSTANI Jihane


Tous les auteurs :
Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O

Résumé

The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer.

Mots clés

Chemoradiation, Immune suppressive cells, Tumor-specific T cell response

Référence

BMC Immunol. 2021 Jun 18;22(1):38